ECTRIMS2016

#ECTRIMS2016 – New Data Show Ocrevus Effective in Treating Primary and Relapsing MS

Positive new data from Phase 3 clinical trials assessing Ocrevus (ocrelizumab) as a treatment for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) were recently announced by Roche, the company responsible for marketing and developing this investigational therapy. The results are being presented at the 32nd Congress of the…

#ECTRIMS2016 – Benefits of Gilenya in MS Also Appear Linked to Its Effects on B-Cells

Scientists recently reported additional mechanisms of action that may underlie Gilenya (fingolimod) beneficial effects in relapsing-remitting multiple sclerosis (RRMS). The results were in an oral presentation, “Fingolimod therapy modulates B cell functions: reduces CXCR4-mediated migration and increases B cell -mediated anti-inflammatory cytokine profile,” given at the 32nd Congress of the European Committee for Treatment…

#ECTRIMS2016 – Cognitive Problems in MS Patients Linked to Lower Income, Study Reports

In a recent talk, titled “Income and cognitive impairment among multiple sclerosis patients,” scientists investigated how cognitive impairment impacts the life of patients with multiple sclerosis (MS), and reported significant differences in income that correlated with levels of MS-cognitive deficit. These findings were recently presented at the 32nd Congress of the European Committee for…

#ECTRIMS2016 – Patient Empowerment Is One of My Highlights for Day 1

Europe’s annual congress discussing treatment, including Patient Empowerment, and research in multiple sclerosis is now underway in London. The 32nd congress is being held from today until Saturday, when it draws to a close at lunchtime. The agenda is absolutely jammed full of topics being covered in a multitude of sessions…

#ECTRIMS2016 – Oryzon to Present Positive Preclinical Data on Potential MS Therapy

Researchers from Oryzon will present efficacy data on the company’s oral epigenetic drug ORY-2001, a potential treatment for multiple sclerosis (MS), at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress taking place this week in London. The poster presentation, “LSD1 inhibition, a potential epigenetic therapeutic approach for the…

#ECTRIMS2016 – Stay Up to Date with My Pick of Congress Highlights

The show comes to town in the next week with ECTRIMS hosting what it describes as “the world’s largest annual international conference” devoted to basic treatment and clinical research in multiple sclerosis. It is being held in London’s ExCel center from Wednesday to Saturday morning, and will be followed…

Gilenya-like Therapy Shows Benefit in Secondary Progressive MS Patients in Phase 3 Trial

Patients with secondary progressive multiple sclerosis (SPMS) who were treated with BAF312 (siponimod), a sphingosine-1-phosphate (S1P) inhibitor, in a Phase 3 clinical trial showed a  significantly reduced risk for disability progression compared to placebo, Novartis recently announced. BAF312 is a selective modulator of specific types of the S1P receptor. This receptor is…